Last update 04 Nov 2024
Chengdu Fendi Pharmaceutical Co., Ltd

Chengdu Fendi Pharmaceutical Co., Ltd

Private Company | Subsidiary Company|
2020|
Sichuan Sheng, China
|

Overview

Basic Info

Introduction
FenDi Pharma Co., Ltd. is an innovative drug development company focused on the field of molecular glue. In May 2021, it secured a RMB 35 million investment from Guangzhou Yipinhong Pharmaceutical, a listed company in China. FenDi Pharma utilizes the ProDeDrug (Protein Degradation Drug) molecular glue rational design platform, pioneering the combination of protein degradation and immune self-regulation mechanisms. The company applies technologies such as artificial intelligence (AI) and molecular simulation in the development of novel molecular glue drugs to expedite the discovery and development of highly efficacious molecules. FenDi Pharma's collaborative projects also explore indications beyond oncology for molecular glue, such as cardiovascular and osteoporosis, and have made significant progress in these areas.

Tags

Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
Molecular glue
Degrader-antibody conjugates

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Molecular glue3
Degrader-antibody conjugates2

Corporation Tree

Boost your research with our corporation tree data.
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
2
Preclinical
Phase 1
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
FD-001
( GSPT1 )
Myelodysplastic Syndromes
More
Phase 1
FD-004
( HER2 )
Neoplasms
More
Preclinical
FD-005
( CD33 )
Neoplasms
More
Preclinical
FD-002
( p53 )
Acute Myeloid Leukemia
More
Discovery
FD-003
Non-Small Cell Lung Cancer
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free